美沙拉嗪从pH依赖性制剂中的释放：奥美拉唑和乳果糖联合给药的影响。
Mesalazine release from a pH dependent formulation: effects of omeprazole and lactulose co-administration.
作者信息
Hussain F N, Ajjan R A, Moustafa M, Weir N W, Riley S A
机构信息
Department of Gastroenterology, Northern General Hospital, Sheffield.
出版信息
Br J Clin Pharmacol. 1998 Aug;46(2):173-5. doi: 10.1046/j.1365-2125.1998.00762.x.
Abstract
AIMS
Delayed-release formulations of mesalazine often rely on the gastrointestinal luminal pH profile to deliver 5-aminosalicylic acid (5ASA) to the colon. The aim of this study was to examine the influence of luminal pH on mesalazine release.
METHODS
We studied the effect of co-administration of omeprazole and lactulose on the steady-state pharmacokinetics of Eudragit S-coated mesalazine in healthy volunteers.
RESULTS
No significant changes in urinary or faecal levels of 5ASA or its main metabolite, N-acetyl 5ASA, were apparent.
CONCLUSIONS
This study suggests that co-administration of omeprazole and lactulose does not impair the release of delayed-release mesalazine.
摘要
目的
美沙拉嗪缓释制剂通常依赖胃肠道腔内的pH值分布将5-氨基水杨酸（5ASA）输送至结肠。本研究的目的是考察腔内pH值对美沙拉嗪释放的影响。
方法
我们研究了在健康志愿者中联合使用奥美拉唑和乳果糖对Eudragit S包衣美沙拉嗪稳态药代动力学的影响。
结果
5ASA及其主要代谢产物N-乙酰5ASA的尿液或粪便水平未见明显变化。
结论
本研究表明，联合使用奥美拉唑和乳果糖不会损害美沙拉嗪缓释制剂的释放。
相似文献
1
Mesalazine release from a pH dependent formulation: effects of omeprazole and lactulose co-administration.美沙拉嗪从pH依赖性制剂中的释放：奥美拉唑和乳果糖联合给药的影响。
Br J Clin Pharmacol. 1998 Aug;46(2):173-5. doi: 10.1046/j.1365-2125.1998.00762.x.
2
Dose loading with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters.缓释美沙拉嗪的负荷剂量：组织药物浓度和标准药代动力学参数的研究
Br J Clin Pharmacol. 2000 Apr;49(4):323-30. doi: 10.1046/j.1365-2125.2000.00164.x.
3
Effect of the proton pump inhibitor omeprazole on the pharmacokinetics of extended-release formulations of oxybutynin and tolterodine.质子泵抑制剂奥美拉唑对奥昔布宁和托特罗定缓释制剂药代动力学的影响。
J Clin Pharmacol. 2005 Aug;45(8):961-8. doi: 10.1177/0091270005278055.
4
Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis.系统评价：用于溃疡性结肠炎治疗的口服美沙拉嗪制剂和美沙拉嗪前体药物的药代动力学特征
Aliment Pharmacol Ther. 2003 Jan;17(1):29-42. doi: 10.1046/j.1365-2036.2003.01408.x.
5
Acid Inhibitory Effect of a Combination of Omeprazole and Sodium Bicarbonate (CDFR0209) Compared With Delayed-Release Omeprazole 40 mg Alone in Healthy Adult Male Subjects.奥美拉唑钠碳酸氢钠（CDFR0209）联合与单独使用延迟释放奥美拉唑 40mg 在健康成年男性受试者中的抑酸效果比较。
Clin Pharmacol Drug Dev. 2018 Jan;7(1):53-58. doi: 10.1002/cpdd.331. Epub 2017 Jan 23.
6
A pharmacokinetic study of sulphasalazine and two new formulations of mesalazine.
Aliment Pharmacol Ther. 1992 Apr;6(2):259-66. doi: 10.1111/j.1365-2036.1992.tb00269.x.
7
Clinical pharmacokinetics of slow release mesalazine.缓释美沙拉嗪的临床药代动力学
Clin Pharmacokinet. 2000 Aug;39(2):85-97. doi: 10.2165/00003088-200039020-00001.
8
Effect of omeprazole on the pharmacokinetics of sustained-release carbamazepine in healthy male volunteers.奥美拉唑对健康男性志愿者中缓释卡马西平药代动力学的影响。
Methods Find Exp Clin Pharmacol. 2001 Jan-Feb;23(1):37-9. doi: 10.1358/mf.2001.23.1.619178.
9
Omeprazole delays gastric emptying in healthy volunteers: an effect prevented by tegaserod.奥美拉唑会延缓健康志愿者的胃排空：替加色罗可预防此效应。
Aliment Pharmacol Ther. 2005 Jul 1;22(1):59-65. doi: 10.1111/j.1365-2036.2005.02528.x.
10
Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.酸泵抑制剂的药代动力学、代谢及相互作用。重点关注奥美拉唑、兰索拉唑和泮托拉唑。
Clin Pharmacokinet. 1996 Jul;31(1):9-28. doi: 10.2165/00003088-199631010-00002.
引用本文的文献
1
Effect of acid-reducing agents on clinical relapse in ulcerative colitis with pH-dependent-released 5-aminosalicylic acid: a multicenter retrospective study in Japan.抑酸剂对pH依赖型释放5-氨基水杨酸治疗的溃疡性结肠炎临床复发的影响：日本一项多中心回顾性研究
Intest Res. 2021 Apr;19(2):225-231. doi: 10.5217/ir.2020.00023. Epub 2020 Aug 18.
2
Drug-drug interaction profiles of proton pump inhibitors.质子泵抑制剂的药物相互作用谱。
Clin Pharmacokinet. 2010 Aug;49(8):509-33. doi: 10.2165/11531320-000000000-00000.
本文引用的文献
1
An oral preparation to release drugs in the human colon.一种在人体结肠释放药物的口服制剂。
Br J Clin Pharmacol. 1982 Sep;14(3):405-8. doi: 10.1111/j.1365-2125.1982.tb01999.x.
2
Rapid healing of duodenal ulcers with omeprazole: double-blind dose-comparative trial.奥美拉唑治疗十二指肠溃疡的快速愈合：双盲剂量对比试验。
Lancet. 1983 Jul 16;2(8342):124-5. doi: 10.1016/s0140-6736(83)90114-9.
3
Effects of lactulose and other laxatives on ileal and colonic pH as measured by a radiotelemetry device.用无线电遥测装置测量乳果糖和其他泻药对回肠和结肠pH值的影响。
Gut. 1974 Dec;15(12):999-1004. doi: 10.1136/gut.15.12.999.
4
5
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.口服包衣5-氨基水杨酸治疗轻至中度活动性溃疡性结肠炎：一项随机研究。
N Engl J Med. 1987 Dec 24;317(26):1625-9. doi: 10.1056/NEJM198712243172603.
6
Delayed-release mesalazine (5-aminosalicylic acid): coat dissolution and excretion in ileostomy subjects.缓释美沙拉嗪（5-氨基水杨酸）：在回肠造口术患者中的包衣溶解及排泄情况
Br J Clin Pharmacol. 1988 Aug;26(2):173-7. doi: 10.1111/j.1365-2125.1988.tb03383.x.
7
Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis.溃疡性结肠炎患者维持治疗中缓释型5-氨基水杨酸（美沙拉嗪）与柳氮磺胺吡啶的比较。
Gastroenterology. 1988 Jun;94(6):1383-9. doi: 10.1016/0016-5085(88)90677-4.
8
Omeprazole versus ranitidine in erosive oesophagitis.奥美拉唑与雷尼替丁治疗糜烂性食管炎的对比
Lancet. 1987 Sep 12;2(8559):621-2. doi: 10.1016/s0140-6736(87)93005-4.
9
Disposition of 5-aminosalicylic acid from 5-aminosalicylic acid-delivering drugs during accelerated intestinal transit in healthy volunteers.健康志愿者在肠道加速转运过程中5-氨基水杨酸递送药物中5-氨基水杨酸的处置情况。
Scand J Gastroenterol. 1989 Dec;24(10):1179-85. doi: 10.3109/00365528909090784.
10
Effect of omeprazole on intragastric and duodenal bulb acidity in duodenal ulcer patients.
Aliment Pharmacol Ther. 1989 Apr;3(2):151-8. doi: 10.1111/j.1365-2036.1989.tb00201.x.
Zotero 插件